---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-038538"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:00:22.657184+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroOne Q2 product revenue surges to $466K; net loss $3.5M; Evo sEEG launched

## Summary
- Product revenue $466K in Q2 (vs $37K YoY); collaboration revenue $1.46M first half from Zimmer deal.
- Net loss $3.5M for Q2 vs $3.1M prior year; operating expenses rose to $3.5M.
- Cash and equivalents $4.6M as of Mar 31, down from $11.1M at Sep 30; no debt.
- Commercial launch of Evo sEEG electrode with Zimmer Biomet; first cases at Mayo and Cleveland Clinic.
- On track to submit 510(k) for OneRF ablation system in Q2 calendar 2023; new VP of Operations appointed.

## SEC filing metadata
- accession: 0001213900-23-038538
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390023038538/0001213900-23-038538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390023038538/ea178248-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-038538
- JSON: https://secwatch.observer/filing/0001213900-23-038538.json
- Plain text: https://secwatch.observer/filing/0001213900-23-038538.txt

## Key facts
- Earnings Releases
  NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal second quarter 2023 ended March 31, 2023 results: revenue product revenue was $466,000, net income Net loss was $3.5 million for the fiscal second quarter 2023.
  - Period: fiscal second quarter 2023 ended March 31, 2023
  - Revenue: product revenue was $466,000
  - Net income: Net loss was $3.5 million for the fiscal second quarter 2023
  - Result: reported results
  source text: Product revenue was $466,000 in the fiscal second quarter 2023, compared to product revenue of $37,000 in the fiscal second quarter 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1500198/000121390023038538/0001213900-23-038538-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.